Audit: QRS - Dutasteride for Hair Regrowth

Audit conducted on 22/09/2026 17:01 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	94
Passed	87
Failed	0
N/A	7
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	Every gate item, tier item, marker row, protocol cell and qualitative item traces to an ER bullet, heading or table row.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“no trial has tested this schedule for hair” (action_2_sub) and “No established on-treatment target” (marker_3_target) carry the ER’s hedging verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain absolute; interactions remain interactions; no hedge is dropped or added.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Benefits come only from Expected Benefits, risks only from Potential Risks & Side Effects, gates only from Key Interactions & Contraindications.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	No PMIDs, citations, expert names or NCT IDs appear; the only drug names (finasteride, minoxidil, tamsulosin etc.) are ER-sourced for the same fact.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind appear in the QRS.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Measured, mechanism-first, non-promotional — matches the ER register.
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Benefit and harm tiers are presented side by side without alarm or advocacy.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol and monitoring cells describe what the literature uses, not what the reader should do.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No imperatives; cadence and targets are stated descriptively.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No “recommended”, “should”, or “advised” anywhere in the sheet.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns appear.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Retained technical terms (CYP3A4, gynaecomastia, angioedema) are decision-gate content required by 9.5/13.3.
2.8	Information is presented in a concise and very compact manner	🟢	Every tier item and gate item is a single noun phrase; no elaboration.
2.9	It DOES NOT address the reader directly	🟢	Confirmed across header, lede, protocol, gates, cards and footer.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional biomarker targets and a baseline-before-first-dose protocol assume a proactive, self-tracking reader.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Nine-marker baseline panel, semen analysis and standardised photography assume effort tolerance.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	Nothing is simplified to a general-population “ask your doctor” level.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	The lede weighs the six-month evidence ceiling against indefinite hormonal suppression, the trade-off that matters to this audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur in the QRS.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt.	🟢	The lede uses “prescription oral medication”; the protocol uses “oral soft gelatin capsule”. No “pill”, “shot” or “taken by mouth”.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All fixed strings match the template byte-for-byte (lines 446, 492, 541, 569, 582, 604, 634, 638–640, 787).
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All 34 named template variables plus the repeatable marker_#* and qualitative_item# spans are present.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	A diff of the head/CSS block against the template shows no change other than the populated <title>.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	The only empty ER subsection (Expected Benefits → Speculative) carries no empty-state phrasing; the case is governed by 12.5 instead.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Standard dose”, “Reduced-frequency alternative” and “Baseline biomarkers” are the ER’s bold labels verbatim; marker names match the ER biomarker table verbatim.
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	Time-to-effect cell labels name the distinct sub-facts inside the ER’s “Time to effect” and “Half-life” bullets, which cannot each carry the same single ER label.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji anywhere; the ER’s ⚠️ and ⭕️ markers were stripped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section is already at minimum granularity — single noun phrases per item, no trailing rationale — and the mandated marker and qualitative lists are carried at their shortest form.

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Lines 2–14, immediately after <!doctype html> on line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment; no element repeats its values.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly so because it contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: dutasteride_hair_2026-0921-1816_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.9.22, matching the QRS.md badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0922-1650.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version, no qualifier.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys, including the workflow-added git_user and git_issue.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Dutasteride for Hair Regrowth - Quick Reference Sheet”; no entity encoding required.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417: “Dutasteride for Hair Regrowth”.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	Line 421: “09/22/2026” from 2026-0922-1650.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header holds only the title and the template subline; the ER’s “Also known as” line was not carried over.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence	🟢	Opens “Dutasteride is a prescription oral medication, licensed for an enlarged prostate, that blocks…” — kind and use stated before any verdict.
7.2	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Mirrors the Conclusion’s three moves: dual block, short-trial benefit with a six-month evidence ceiling, mechanism-linked harms.
7.3	[at_a_glance] is no longer than 70 words	🟢	69 words.
7.4	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	Each clause maps to ER lines 513, 515 and 517 plus the Motivation licensing statement.
7.5	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	“enlarged prostate”, “the enzyme making the hormone”, “inherited pattern hair loss” — no DHT, 5-ARI, BPH or androgenetic alopecia.
7.6	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Only “short trials” in the aggregate.
7.7	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers other than “six months”.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All six items come from the “Populations who should avoid Dutasteride” list (ER lines 349–354).
8.2	[stop_items] represent the Contraindications from the ER	🟢	All six ER populations are present, none added.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Six <li> elements inside the span (lines 572–577).
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every ER trailing clause after the em-dash (“capsules must not even be handled”, “the 5-week half-life means…”) is stripped.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	“within the next 6 months”, “within 6 months of the last dose”, “(Child-Pugh Class C)” and “under 18 years” all retained.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER uses no ranking notation in this list; no bare symbols were carried through.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names six such populations and the section is correspondingly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All seven items come from the ER interaction bullets (lines 333–345).
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	All seven ER interactions present; no overlap with the contraindication list.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Seven <li> elements inside the span (lines 585–594).
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s Caution/Monitor verdicts, consequences and mitigations are all stripped; only the agent name remains.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All four ER parenthetical drug lists are carried verbatim, as is “(over-the-counter acid reducer)”.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	🟢	The ER’s parentheses are already plain comma-separated lists; no symbols carried through.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names seven interactions and the section is correspondingly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells come from the ER Therapeutic Protocol bullets (lines 378, 380, 402).
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	Standard dose, reduced-frequency alternative and the pre-treatment biomarker panel are the three load-bearing execution decisions in that section.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies more than three actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	All nine spans carry ER-derived content; no placeholders remain.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Maximum effect near 12 months, visible change at 3–6 months and steady state at ~6 months — the three intervals the ER states (lines 390, 439).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Ordered from fullest hair response down to the pharmacokinetic anchor.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	All nine spans carry ER-derived content, including the initial-shedding pitfall and the 5-week terminal half-life.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER provides explicit time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	All eight items are ER benefit headings.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present (lines 543, 550, 556, 562).
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to a noun phrase; no magnitudes or trial detail carried over.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in the Benefits card.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	The ER’s Speculative benefits subsection is empty and the span at line 562 carries style="display: none" with no content.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	All twelve items are ER risk headings across the four tiers.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present and populated (lines 606, 612, 620, 626).
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Each item is the ER heading reduced to a noun phrase; no hazard ratios, confidence intervals or trial names.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses appear in the Risk & Side Effects card.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	N/A	All four ER risk tiers contain items, so no span needed hiding.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Rows and cadence come from the ER Monitoring Protocol & Defining Success section (lines 467–481).
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER biomarker-table rows are present in ER order, with targets and rationales preserved.
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 778: baseline, 6-month and 12-month hormone/PSA repeats and the photography schedule, matching ER line 469.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	All seven items come from the ER’s “Qualitative markers tracked alongside the laboratory values” list (lines 485–491).
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All seven ER qualitative markers are carried, none dropped or added.

Issues 22/09/2026 17:01

Pass rate 100.00%. No issues found.

Issues 22/09/2026 16:55

1. 1.1 / 1.3 / 7.4 — At-A-Glance overstates data gap: The lede (line 437) states “longer data are absent”, but the ER records that durability beyond six months “rests on uncontrolled extension data” (ER line 161) and that “almost all of it stops at six months” (ER line 515) — an absence claim the ER does not make.
2. 9.5 — Cimetidine parenthetical dropped: Line 590 lists “Cimetidine” without the ER bullet’s parenthetical “(over-the-counter acid reducer)” (ER line 337), while the neighbouring CYP3A4 and alpha-blocker items keep theirs.

Fixes 22/09/2026 16:55

1. 1.1 / 1.3 / 7.4 — At-A-Glance data-gap claim: Replaced “longer data are absent” with “almost all the evidence stops there”, matching the ER Conclusion; the lede remains within the 70-word budget at 69 words.
2. 9.5 — Cimetidine parenthetical restored: Changed the Key Interactions item from “Cimetidine” to “Cimetidine (over-the-counter acid reducer)”, reinstating the ER bullet’s parenthetical.